Novo Nordisk shares dive 9% after heart medicine fails trial
business
Novo Nordisk shares dropped nine percent after the company's heart medicine failed a clinical trial, per CNBC. The result represents a setback for the pharmaceutical company's drug development pipeline.
Source: https://www.cnbc.com/2026/07/31/novo-nordisk-trial-results.html
Listen to this story
Hear this and more stories in a personalized audio briefing.
Open The Chonkerton